Analyst Consensus ?
ConsensusHold38 ratings
Bullish1436.9%
Neutral2360.5%
Bearish12.6%
1 unmapped firm rating excluded from the percentages.
Pfizer Inc. · PFE · FY2026 Q2 · Calendar Q3 2026
Pfizer Q2 2026: Revenue beat, guidance raised, pipeline advances
Pfizer's Q2 update strengthened the near-term growth case through a revenue beat, higher full-year revenue guidance, acquired-product growth and cost savings. The longer-term case remains dependent on pipeline execution, regulatory approvals, management of legacy-product losses and the durability of non-COVID growth.
Reported Before market openNYSEHealthcare
$158.10B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.77
Consensus $0.68
EPS surprise
+12.9%
Reported versus consensus
Reported revenue
$15.03B
Consensus $14.40B
Revenue surprise
+4.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+1.5%
Event window
SPY move
+1.8%
Same window
Abnormal move
-0.3%
Stock minus SPY
Volume
1.6×
Versus trailing sessions
Subsequent drift
+12.4%
Up to 20 sessions
PFESPY benchmark
Ask FN2 about PFE FY2026 Q2
Transcript, numbers and history already loaded
Why did PFE rise 1.5% after beating EPS estimates in FY2026 Q2?What changed in PFE's guidance and outlook in FY2026 Q2?Give me the bull and bear case for PFE after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management moved from maintained guidance to raised revenue guidance while reaffirming EPS guidance. The update also added evidence of progress from acquired products, cost savings, the pipeline and AI-enabled operating improvements.
Guidance delta
Management raised the full-year 2026 revenue midpoint while reaffirming EPS guidance.
Key takeaways
- Management said Q2 revenue and adjusted EPS exceeded expectations, with growth from legacy and acquired products including Eliquis, Padcev and NURTEC.
- The company said cost-saving initiatives remain on track for about $9.7 billion in net savings through 2029.
- Pipeline progress included berobenatide in obesity, Litfulo in vitiligo and multiple oncology ADC programs.
- Management positioned AI as a contributor to R&D productivity, manufacturing efficiency and cost reduction.
Management priorities
- Advance Phase III programs in obesity, oncology and immunology.
- Continue integrating acquired Seagen, Metsera and Biohaven assets.
- Expand the AI-native R&D platform and manufacturing optimization.
- Maintain cost discipline and reinvest savings in growth programs.
Follow PFE with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$27.93Current
$20Low
$39.19Average
$70High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 23, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| HSBC | Hold | Hold | Maintain | Sep 10, 2026 |
| Guggenheim | Buy | Buy | Maintain | Aug 7, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 13, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jul 10, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 8, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Jul 6, 2026 |
| RBC Capital | Sector Perform | Underperform | Upgrade | Jun 10, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Apr 29, 2026 |
| UBS | Neutral | Neutral | Maintain | Apr 13, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Apr 10, 2026 |
| Argus Research | Buy | Hold | Upgrade | Mar 2, 2026 |
| Freedom Broker | Buy | Buy | Maintain | Feb 9, 2026 |
| Goldman Sachs | Neutral | Buy | Downgrade | Apr 8, 2025 |
| Truist Securities | Buy | Buy | Maintain | Dec 18, 2024 |
| Daiwa Capital | Outperform | Neutral | Upgrade | Aug 8, 2024 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 31, 2024 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 31, 2024 |
| TD Cowen | Market Perform | Outperform | Downgrade | Jan 4, 2024 |
| Jefferies | Buy | Hold | Upgrade | Oct 16, 2023 |
| Credit Suisse | Neutral | Outperform | Downgrade | Jun 29, 2023 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Feb 1, 2023 |
| Atlantic Equities | Neutral | Neutral | Maintain | Feb 1, 2023 |
| Mizuho | Neutral | Neutral | Maintain | Dec 14, 2021 |
| DZ Bank | Buy | Hold | Upgrade | Feb 4, 2021 |
| Bernstein | Perform | Market Perform | Maintain | Nov 10, 2020 |
| Berenberg | Hold | Hold | Maintain | Sep 29, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Jul 30, 2019 |
| Argus | Outperform | Neutral | Upgrade | Jan 31, 2019 |
| Leerink Swann | Market Perform | Market Perform | Maintain | Jan 31, 2018 |
| Societe Generale | Hold | Hold | Maintain | Apr 6, 2016 |
| SunTrust Robinson Humphrey | Neutral | Neutral | Maintain | Feb 16, 2016 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Oct 20, 2015 |
| PiperJaffray | Overweight | Overweight | Maintain | Jun 17, 2015 |
| Deutsche Bank | Buy | Buy | Maintain | Apr 28, 2015 |
| LBBW Research | Buy | Hold | Upgrade | Nov 14, 2013 |
| Standpoint Research | Sell | Hold | Downgrade | Jul 2, 2013 |
| Hilliard Lyons | Long Term Buy | Maintain | Jan 29, 2013 | |
| MKM Partners | Neutral | Buy | Downgrade | Nov 27, 2012 |
| ISI Group | Buy | Buy | Maintain | Apr 9, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $27.93. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| HSBC | Analyst unavailable | $30 | $27.78 | +7.4% | Sep 10, 2026 |
| Guggenheim | Analyst unavailable | $31 | $26.2 | +11.0% | Aug 7, 2026 |
| HSBC | Analyst unavailable | $28 | $24.32 | +0.3% | Jul 6, 2026 |
| UBS | Michael Yee | $27 | $26.34 | -3.3% | May 27, 2026 |
| Wolfe Research | Alexandria Hammond | $26 | $25.96 | -6.9% | May 14, 2026 |
| Morgan Stanley | Terence Flynn | $27 | $27.06 | -3.3% | Mar 17, 2026 |
| BMO Capital | Evan David Seigerman | $30 | $26.48 | +7.4% | Mar 9, 2026 |
| RBC Capital | Trung Huynh | $25 | $27.14 | -10.5% | Feb 24, 2026 |
| Barclays | Emily Field | $25 | $26.86 | -10.5% | Feb 19, 2026 |
| Daiwa | Narumi Nakagiri | $27 | $27.73 | -3.3% | Feb 12, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $27 | $25.88 | -3.3% | Jan 27, 2026 |
| UBS | Analyst unavailable | $25 | $25.43 | -10.5% | Jan 6, 2026 |
| Wolfe Research | Alexandria Hammond | $24 | $25.53 | -14.1% | Dec 17, 2025 |
| Morgan Stanley | Analyst unavailable | $28 | $25.89 | +0.3% | Dec 12, 2025 |
| HSBC | Rajesh Kumar | $29 | $25.33 | +3.8% | Dec 10, 2025 |
| Guggenheim | Analyst unavailable | $35 | $25.17 | +25.3% | Nov 24, 2025 |
| Goldman Sachs | Asad Haider | $26 | $24.22 | -6.9% | Nov 5, 2025 |
| Bernstein | Courtney Breen | $30 | $24.45 | +7.4% | Oct 31, 2025 |
| Morgan Stanley | Analyst unavailable | $32 | $25.24 | +14.6% | Oct 10, 2025 |
| UBS | Tim Anderson | $28 | $27.16 | +0.3% | Oct 1, 2025 |
| Cantor Fitzgerald | Carter Gould | $24 | $22.53 | -14.1% | Apr 22, 2025 |
| Truist Financial | Robyn Karnauskas | $32 | $25.89 | +14.6% | Dec 18, 2024 |
| Goldman Sachs | Chris Shibutani | $33 | $28.46 | +18.2% | Oct 30, 2024 |
| Bernstein | Courtney Breen | $32 | $29.67 | +14.6% | Oct 17, 2024 |
| Barclays | Carter Gould | $32 | $28.93 | +14.6% | Sep 25, 2024 |
| Daiwa | Narumi Nakagiri | $34 | $28.85 | +21.7% | Aug 7, 2024 |
| Wells Fargo | Mohit Bansal | $30 | $31.39 | +7.4% | Jul 31, 2024 |
| Goldman Sachs | Chris Shibutani | $34 | $31.39 | +21.7% | Jul 31, 2024 |
| Guggenheim | Vamil Divan | $36 | $30.72 | +28.9% | Jul 30, 2024 |
| Barclays | Carter Gould | $30 | $27.72 | +7.4% | Jul 10, 2024 |
| BMO Capital | Evan Seigerman | $36 | $29.6 | +28.9% | May 22, 2024 |
| Cantor Fitzgerald | Louise Chen | $45 | $26.97 | +61.1% | Feb 14, 2024 |
| Morgan Stanley | Thomas Yeh | $20 | $26.92 | -28.4% | Dec 14, 2023 |
| Morgan Stanley | Terence Flynn | $37 | $30.5 | +32.5% | Nov 27, 2023 |
| Morgan Stanley | Analyst unavailable | $45 | $43.84 | +61.1% | Feb 1, 2023 |
| Credit Suisse | Analyst unavailable | $50 | $43.59 | +79.0% | Feb 1, 2023 |
| Barclays | Analyst unavailable | $44 | $44.16 | +57.5% | Feb 1, 2023 |
| Atlantic Equities | Analyst unavailable | $46 | $44.16 | +64.7% | Feb 1, 2023 |
| Leerink Partners | Analyst unavailable | $48 | $44.16 | +71.9% | Feb 1, 2023 |
| Morgan Stanley | Analyst unavailable | $53 | $54.73 | +89.8% | Dec 14, 2022 |
| Goldman Sachs | Chris Shibutani | $60 | $53.37 | +114.8% | Dec 13, 2022 |
| Credit Suisse | Analyst unavailable | $55 | $48.33 | +96.9% | Nov 18, 2022 |
| Leerink Partners | David Risinger | $55 | $52.88 | +96.9% | May 23, 2022 |
| Wells Fargo | Mohit Bansal | $54.42 | $19.11 | +94.8% | May 10, 2022 |
| Wells Fargo | Mohit Bansal | $55 | $49.04 | +96.9% | May 9, 2022 |
| Morgan Stanley | Analyst unavailable | $52 | $49.68 | +86.2% | May 4, 2022 |
| Mizuho Securities | Vamil Divan | $55 | $49.07 | +96.9% | May 2, 2022 |
| Cantor Fitzgerald | Louise Chen | $75 | $53.12 | +168.5% | Apr 15, 2022 |
| Morgan Stanley | Terrance Flynn | $55 | $55.17 | +96.9% | Apr 10, 2022 |
| Citigroup | Andrew Baum | $57 | $55.17 | +104.1% | Apr 9, 2022 |
| Bank of America Securities | Geoff Meacham | $70 | $50.27 | +150.6% | Mar 12, 2022 |
| Barclays | Carter Gould | $54 | $51.7 | +93.3% | Feb 8, 2022 |
| Goldman Sachs | Chris Shibutani | $50 | $51.7 | +79.0% | Feb 8, 2022 |
| J.P. Morgan | Chris Schott | $57 | $51.7 | +104.1% | Feb 8, 2022 |
| BMO Capital | Evan Seigerman | $76 | $54.95 | +172.1% | Jan 15, 2022 |
| Bernstein | Aaron Gal | $65 | $56.22 | +132.7% | Jan 3, 2022 |
| Leerink Partners | Geoff Porges | $56 | $59.1 | +100.5% | Dec 22, 2021 |
| UBS | Colin Bristow | $60 | $54.78 | +114.8% | Dec 13, 2021 |
| Independent Research | Tobias Gottschalt | $54 | $49.8 | +93.3% | Nov 11, 2021 |
| Wolfe Research | Tim Anderson | $46 | $44.09 | +64.7% | Nov 3, 2021 |
| RBC Capital | Daniel Busby | $44 | $42.1 | +57.5% | Jul 29, 2021 |
| Argus Research | David Toung | $55 | $37.54 | +96.9% | Jun 1, 2021 |
Track every rating change on PFE the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationPfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid.…
Historical context
All PFE earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
| A Agilent Technologies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +8.7% | +1.7% | Agilent raises outlook after Q3 beat; Ignite drives margin gains |
Latest beats and misses
Who reports nextBeat on EPS
- FPSFY2026 Q4 · September 15, 2026+4.3% EPS+9.5% move
- TCOMFY2026 Q2 · September 15, 2026+22.3% EPS+3.0% move
- KRFY2026 Q2 · September 11, 2026+2.8% EPS+2.7% move
- ADBEFY2026 Q3 · September 10, 2026+0.8% EPS+1.4% move
- ORCLFY2027 Q1 · September 10, 2026+10.3% EPS-1.7% move
- CASYFY2027 Q1 · September 8, 2026+8.7% EPS-14.2% move
Get the PFE recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-08-04T21:12:29.664171+00:00
- FN2 earnings calendar · 2026-09-09T01:23:14.388487+00:00
- Polygon adjusted daily market bars · 2026-09-22T22:20:52.913539+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-22T22:20:52.910522+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-22. For educational purposes only; not investment advice.